Objective
, as the model included treatment switches, which were not included in the clinical trial. ■ These treatment switches, from the first line treatment to the second line treatment, took place at 2.7 and 2.8years post-start of the model analysis. ■ However, weight change in the model can still be compared with the data by Del Prato et al. 2013 5 at week-104 (year 2), before the first treatment switch. Both the model and the clinical trial present data for that time point. ■ Within the model it was seen that, at week 104, the weight change for the MET + DAPA and MET + SU algorithm was -3.22 kg and +1.44 kg respectively, resulting in a difference of weight of -4.66 kg, in favour of MET + DAPA. This difference in weight is comparable to what is observed from the clinical trial data. Model structure ■ The peer-reviewed and published CARDIFF diabetes modelling framework [7] [8] [9] , a lifelong micro-markov stochastic simulation model, was used to assess disease progression and the cost-effectiveness. ■ Basic simulation settings were similar to previous research 6 . ■ A discount rate of 3.5 % was applied to both costs and health effects, as suggested by NICE 10 . ■ A lifetime horizon was applied to capture the chronic nature of the disease.
Target population and treatment sequences ■ Patient population: T2DM patients for whom MET alone does not provide adequate glycaemic control.
Effect parameters
■ As the simulation progresses, age, duration of diabetes and modifiable risk factor parameters change, due to treatment effects and/or natural progression. ■ During the first year, the changes in HbA1c, weight, SBP and cholesterol were applied based on results of the randomised clinical trials, published by Nauck et al. Cost parameters ■ UK specific sources and assumptions, previously reported by Charokopou et al. 2013 6 , were used to retrieve cost inputs related to drug acquisition, diabetes-related complications, adverse events (one general practitioner visit cost), discontinuation of treatment, hypoglycaemia and renal monitoring costs (assumed to incur one general practitioner visit cost and a 24-hour urine creatinine clearance determination). An overview of the applied drug acquisition costs can be seen in Table 3 . has been used before for assessment of other diabetic agents by health authorities.
Quality of life parameters

Sensitivity analyses
■ The tornado graphs on incremental costs and effects, resulting from the deterministic sensitivity analyses, are presented in Figure 3 .
■ The PSA showed that at a threshold of £ 20,000, the probability of the MET + DAPA treatment algorithm being cost-effective, over the MET + SU treatment algorithm, was 100 % ( Figure 5 ). Additionally, 100 % of the simulations resulted in ICURs being in the upper-right of the PSA scatterplot, denoting that at an additional cost, more QALYs can be gained, in comparison to the MET + SU treatment algorithm ( Figure 4 ).
■ The impact of uncertainty on results, was investigated using deterministic univariate analyses (UA) and a multivariate probabilistic sensitivity analysis (PSA). ■ Two additional scenarios were conducted to address the uncertainty of parameters or choices that could not be fully captured by the UA and PSA: ■ First scenario: Utility values, assigned to BMI change, were set to zero to observe the impact of full absence of health effects related to BMI changes. ■ Second Scenario: HbA1c switching threshold and baseline HbA1c were set to 7%
Presented at: 17th Annual European Congress. Amsterdam RAI, Amsterdam, The Netherlands November 8-12, 2014 , as the source of BMI change-related utility values, for the present analysis, for reasons outlined in the Methods section. ■ It is yet uncertain how weight progresses over time when patients discontinue a treatment associated with weight loss. ■ Treatment switches in the model happen when a predefined HbA1c threshold is reached. In a clinical setting, however, other factors may lead to a switch, such as worsening of adverse events, disease. These factors are not captured in our analyses.
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